Our findings showed that the AMPK activator, AICAR, exhibited synergistic antitumor effects when combined with anti-PD-1 and anti-CTLA4 antibodies, suggesting that AMPK activators could be considered to complement anti-PD-1 and anti-CTLA4 therapy to improve the outcomes of cancer patients. The gene discussed is PRKAA2; the disease is cancer.